Dianthus Therapeutics (DNTH) Competitors $22.15 +0.38 (+1.75%) Closing price 01/31/2025 04:00 PM EasternExtended Trading$22.16 +0.01 (+0.02%) As of 01/31/2025 04:02 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends DNTH vs. GMTX, HCM, MIRM, CGON, PTGX, JANX, VERA, HRMY, IBRX, and CNTAShould you be buying Dianthus Therapeutics stock or one of its competitors? The main competitors of Dianthus Therapeutics include Gemini Therapeutics (GMTX), HUTCHMED (HCM), Mirum Pharmaceuticals (MIRM), CG Oncology (CGON), Protagonist Therapeutics (PTGX), Janux Therapeutics (JANX), Vera Therapeutics (VERA), Harmony Biosciences (HRMY), ImmunityBio (IBRX), and Centessa Pharmaceuticals (CNTA). These companies are all part of the "pharmaceutical products" industry. Dianthus Therapeutics vs. Gemini Therapeutics HUTCHMED Mirum Pharmaceuticals CG Oncology Protagonist Therapeutics Janux Therapeutics Vera Therapeutics Harmony Biosciences ImmunityBio Centessa Pharmaceuticals Gemini Therapeutics (NASDAQ:GMTX) and Dianthus Therapeutics (NASDAQ:DNTH) are both medical companies, but which is the better stock? We will compare the two businesses based on the strength of their valuation, earnings, community ranking, media sentiment, profitability, analyst recommendations, risk, institutional ownership and dividends. Which has better valuation & earnings, GMTX or DNTH? Dianthus Therapeutics has higher revenue and earnings than Gemini Therapeutics. Gemini Therapeutics is trading at a lower price-to-earnings ratio than Dianthus Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioGemini TherapeuticsN/AN/A-$71.87M-$1.00-55.60Dianthus Therapeutics$2.83M231.67-$43.56M-$2.50-8.86 Which has more risk and volatility, GMTX or DNTH? Gemini Therapeutics has a beta of -0.12, suggesting that its stock price is 112% less volatile than the S&P 500. Comparatively, Dianthus Therapeutics has a beta of 1.74, suggesting that its stock price is 74% more volatile than the S&P 500. Is GMTX or DNTH more profitable? Gemini Therapeutics has a net margin of 0.00% compared to Dianthus Therapeutics' net margin of -1,250.32%. Dianthus Therapeutics' return on equity of -21.68% beat Gemini Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Gemini TherapeuticsN/A -38.78% -35.88% Dianthus Therapeutics -1,250.32%-21.68%-20.88% Does the MarketBeat Community believe in GMTX or DNTH? Dianthus Therapeutics received 4 more outperform votes than Gemini Therapeutics when rated by MarketBeat users. Likewise, 95.83% of users gave Dianthus Therapeutics an outperform vote while only 63.33% of users gave Gemini Therapeutics an outperform vote. CompanyUnderperformOutperformGemini TherapeuticsOutperform Votes1963.33% Underperform Votes1136.67% Dianthus TherapeuticsOutperform Votes2395.83% Underperform Votes14.17% Does the media refer more to GMTX or DNTH? In the previous week, Dianthus Therapeutics had 2 more articles in the media than Gemini Therapeutics. MarketBeat recorded 3 mentions for Dianthus Therapeutics and 1 mentions for Gemini Therapeutics. Gemini Therapeutics' average media sentiment score of 1.22 beat Dianthus Therapeutics' score of 0.46 indicating that Gemini Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Gemini Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Dianthus Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Do insiders and institutionals hold more shares of GMTX or DNTH? 75.4% of Gemini Therapeutics shares are owned by institutional investors. Comparatively, 47.5% of Dianthus Therapeutics shares are owned by institutional investors. 12.9% of Gemini Therapeutics shares are owned by company insiders. Comparatively, 16.6% of Dianthus Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth. Do analysts prefer GMTX or DNTH? Dianthus Therapeutics has a consensus target price of $46.43, suggesting a potential upside of 109.61%. Given Dianthus Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Dianthus Therapeutics is more favorable than Gemini Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Gemini Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Dianthus Therapeutics 0 Sell rating(s) 0 Hold rating(s) 8 Buy rating(s) 2 Strong Buy rating(s) 3.20 SummaryDianthus Therapeutics beats Gemini Therapeutics on 13 of the 17 factors compared between the two stocks. Get Dianthus Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for DNTH and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart DNTH vs. The Competition Export to ExcelMetricDianthus TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$617.39M$6.88B$5.58B$9.12BDividend YieldN/A2.90%5.31%3.99%P/E RatioN/A4.5158.9914.21Price / Sales231.67320.231,258.0383.19Price / CashN/A73.5045.9637.70Price / Book1.945.275.124.71Net Income-$43.56M$136.98M$111.17M$224.24M7 Day Performance4.43%-0.59%2.37%-0.17%1 Month Performance1.61%0.18%3.19%0.60%1 Year Performance6.90%7.68%24.69%20.43% Dianthus Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)DNTHDianthus Therapeutics1.9478 of 5 stars$22.15+1.7%$46.43+109.6%+16.6%$617.39M$2.83M0.0080Short Interest ↑GMTXGemini TherapeuticsN/A$57.45+0.8%N/A-15.4%$2.49BN/A-57.4530Positive NewsHigh Trading VolumeHCMHUTCHMED3.3878 of 5 stars$13.64+0.6%$19.00+39.3%+8.2%$2.38B$838M0.001,988Short Interest ↓Positive NewsMIRMMirum Pharmaceuticals3.5652 of 5 stars$48.48+2.0%$57.10+17.8%+84.7%$2.33B$186.37M-24.00140CGONCG Oncology2.2258 of 5 stars$30.50-0.9%$63.88+109.4%-19.3%$2.32B$200,000.000.0061Positive NewsPTGXProtagonist Therapeutics3.2341 of 5 stars$38.36+1.8%$53.78+40.2%+51.1%$2.29B$60M14.42120Positive NewsJANXJanux Therapeutics3.3703 of 5 stars$43.54-1.3%$89.90+106.5%+407.9%$2.28B$8.08M-37.2130Short Interest ↑Positive NewsVERAVera Therapeutics2.8757 of 5 stars$34.84+2.7%$68.86+97.6%+2.4%$2.21BN/A-13.3540Analyst ForecastHRMYHarmony Biosciences4.6231 of 5 stars$38.25+0.6%$55.00+43.8%+22.9%$2.18B$582.02M18.13200Insider TradeIBRXImmunityBio2.4033 of 5 stars$3.13-1.3%$13.58+334.0%+2.7%$2.18B$7.33M-3.40590Short Interest ↑CNTACentessa Pharmaceuticals3.604 of 5 stars$16.42-0.2%$25.83+57.3%+106.6%$2.16B$6.85M-10.73200Insider Trade Related Companies and Tools Related Companies Gemini Therapeutics Alternatives HUTCHMED Alternatives Mirum Pharmaceuticals Alternatives CG Oncology Alternatives Protagonist Therapeutics Alternatives Janux Therapeutics Alternatives Vera Therapeutics Alternatives Harmony Biosciences Alternatives ImmunityBio Alternatives Centessa Pharmaceuticals Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:DNTH) was last updated on 2/1/2025 by MarketBeat.com Staff From Our PartnersElon’s #1 AI Stock” SET TO SOARForget ChatGPT! Because Elon Musk's AI promises to be 100x more powerful.Behind the Markets | SponsoredNow that Trump’s be inaugurated, this day will be key (mark your calendar)Mark your calendar for March 13th. Because on that day, I believe we could see a $2 Trillion shock INTO the...Timothy Sykes | SponsoredWill DeepSeek pop the AI bubble?An overseas AI rival sent shockwaves through the U.S. tech market last week... Leaving millions of investor...Chaikin Analytics | SponsoredBetter than Bitcoin – and potentially more profitableThe world is obsessed with Bitcoin again... And for a good reason: It just soared beyond $100,000. Bitcoin ...Brownstone Research | SponsoredTrump vs. TexasEver since Donald Trump won the election, U.S. states have been rushing to pass new currency rules. These r...Stansberry Research | SponsoredTurning Panic Into OpportunityAI stocks were hammered on Jan. 27. That includes Nvidia, the undisputed leader in the artificial intellige...Weiss Ratings | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | SponsoredWill Elon trigger another AI flash crash?AI continues to dominate financial headlines in 2025...Altimetry | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Dianthus Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Dianthus Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
